Influenza News and Research RSS Feed - Influenza News and Research

Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.
New white paper provides overview of factors that drive vaccination underutilization in older adults

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance. [More]
Hoaglund Enterprises awarded contract to evaluate Avian Flu affected equipment

Hoaglund Enterprises awarded contract to evaluate Avian Flu affected equipment

Hoaglund Enterprises, Inc.,dba Asset Equipment Appraisals & Brokerage, a leading Nationally Certified Appraisal company is pleased to announce that they have been awarded a contract to appraise Avian Flu affected equipment that cannot be disinfected on infected farms by the USDA. [More]
Southampton scientists set to analyse investments into infectious disease research

Southampton scientists set to analyse investments into infectious disease research

Scientists at the University of Southampton are set to analyse research investments into infectious disease research, particularly pneumonia and maternal and neonatal infections, after receiving over £370,000 in funding from the Bill & Melinda Gates Foundation. [More]
Researchers develop diagnostic test to detect enterovirus D68

Researchers develop diagnostic test to detect enterovirus D68

Researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year. The outbreak caused infections at an unprecedented rate, with over 1,000 confirmed cases and 14 reported deaths nationwide, according to the Centers for Disease Control and Prevention. [More]
AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune response of inactivated influenza vaccines) increased the immune responses to two doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest amount of antibody response, according to a study in the July 21 issue of JAMA. [More]
Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

The negative health effects of international air travel are well documented but now it seems that the common elderberry can provide some relief. [More]
Researchers devise way to induce protective immunity in mice against influenza viruses

Researchers devise way to induce protective immunity in mice against influenza viruses

A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain. [More]
Chicago creates sustainable network to meet complicated public health emergencies

Chicago creates sustainable network to meet complicated public health emergencies

The Ebola epidemic and resulting international public health emergency is referred to as a "Black Swan" event in medical circles because of its unpredictable and impactful nature. However, a paper in the June 30 issue of Clinical Infectious Diseases, a leading journal in the field of infectious diseases, suggests that the response of the Chicago Ebola Response Network (CERN) in 2014-2015 has laid a foundation and a roadmap for how a regional public health network can anticipate, manage and prevent the next Black Swan public health event. [More]
GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to US healthcare providers, following licensing and lot-release approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research. [More]
FDA grants CLIA waiver for Alere i Strep A test

FDA grants CLIA waiver for Alere i Strep A test

Alere Inc., a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration has granted CLIA waiver for the Alere i Strep A test. The test, which was cleared for marketing by the FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less. [More]
Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Immunologists from Emory University have identified a distinct set of long-lived antibody-producing cells in the human bone marrow that function as an immune archive. [More]
UK investment lacking for pneumonia research

UK investment lacking for pneumonia research

UK investment in pneumonia research is lacking when compared to spending on influenza and tuberculosis, according to a new study by the University of Southampton and University College London. [More]
New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful. [More]
New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

Viruses, not bacteria, are the most commonly detected respiratory pathogens in U.S. adults hospitalized with pneumonia, according to a New England Journal of Medicine study released today and conducted by researchers at Centers for Disease Control and Prevention and hospitals in Chicago and Nashville, including Vanderbilt University Medical Center. [More]
Creating more effective vaccines against flu virus

Creating more effective vaccines against flu virus

Flu vaccines can be something of a shot in the dark. Not only must they be given yearly, there's no guarantee the strains against which they protect will be the ones circulating once the season arrives. New research by Rockefeller University scientists and their colleagues suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus. [More]
Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Is it possible to predict the evolution of the influenza virus? Or how rapidly bacteria evolve resistance to antibiotics? Or even how cancer cells spread inside a human being? These are some of the main topics of discussion that bring together renowned scientists from all over the world at the scientific conference "Forecasting evolution?" held at the Calouste Gulbenkian Foundation (FCG; Portugal) from 8th to 11th July. [More]
BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

​BiondVax Pharmaceuticals Ltd. today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program. [More]
Mortality rates vary depending on socioeconomic differences among areas in Europe

Mortality rates vary depending on socioeconomic differences among areas in Europe

For a number of years now, scientific literature has questioned whether mortality rates depend on socioeconomic differences among the population. Recently, a new study carried out in 15 European cities - including Barcelona and Madrid - detected inequalities for the majority of causes, concluding that higher levels of poverty are associated with higher mortality rates and there is a great deal of variation among areas. [More]
Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

An international research team led by Lukas Tamm of the University of Virginia School of Medicine will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans. [More]

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

BiondVax Pharmaceuticals Ltd. today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's candidate for a universal influenza vaccine. [More]
Advertisement
Advertisement